ArticleNature communications2026
A Mechanophenotyping chip for high-throughput detection of metastatic bacteria-infected circulating tumor cells.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- iEVIP: a dual-inspired intelligent platform for smart response extracellular vesicle isolation and single-vesicle profiling.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Emerging evidence underscores biophysical characteristics of cancer cells as key modulators of cancer progression and metastasis. Herein, we reported a cell-mechanophenotyping screening microfluidic chip (termed LesM) for the high-efficient capture of circulating tumor cells (CTCs) and evaluation of single-cell deformation to reveal the hematogenous metastatic potential of bacteria-infected breast cancer. LesM employs L-shaped traps to capture single cells, leveraging bacteria-infected CTCs with cytoskeletal reorganization traverse narrowed channels while rigid native cells are retained. The platform demonstrates an average single-cell capture efficiency of 95.42% and specificity of 85.34% in discriminating infected versus non-infected breast cancer cells, validated through parallel in vivo metastatic assays. LesM enables high-throughput sensing up to 10,240 cells of mechanical signatures and microbial cargo, correlating with metastatic risk and antibiotic response. By bridging biomechanics and intratumoral microbiota detection, LesM offers a transformative liquid biopsy tool for predicting distant metastasis and guiding antimicrobial therapies in bacteria-infected breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.